Search
teplizumab (Tzield)
Indications:
- indicated to delay the progression of diabetes mellitus type 1
- approved for adults & pediatric patients >= 8 years with stage 2 type 1 diabetes who want to delay the onset of stage 3, the irreversible stage when insulin- producing beta-cells lose ability to maintain normal glycemic control
Dosage:
- premedicate & treat symptoms with antipyretics, antihistamines, &/or antiemetics
Adverse effects:
- most common
- lymphopenia, rash, leukopenia, headache
- hepatotoxicity
- warning of cytokine release syndrome
Mechanism of action:
- anti-CD3 monoclonal antibody
- believed to work by deactivating immune cells that attack insulin-producing beta-cells, while increasing the proportion of cells that help moderate the immune response
- may delay clinical diagnosis of type 1 diabetes by months to years
General
endocrine agent
monoclonal antibody
References
- Lou N
FDA Approves First Drug to Delay Onset of Type 1 Diabetes.
Teplizumab will not be subject to a risk evaluation and mitigation strategy
program, after all.
MedPage Today November 18, 2022
https://www.medpagetoday.com/endocrinology/type1diabetes/101823